ID   M059J
AC   CVCL_0400
SY   Mo 59J; MO59J
DR   CLO; CLO_0007445
DR   EFO; EFO_0005697
DR   MCCL; MCC:0000294
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2366
DR   BCRC; 60382
DR   BCRJ; 0151
DR   BioSample; SAMN03471832
DR   BioSample; SAMN03473044
DR   CCLE; M059J_CENTRAL_NERVOUS_SYSTEM
DR   Cell_Model_Passport; SIDM00659
DR   ChEMBL-Cells; CHEMBL3308113
DR   ChEMBL-Targets; CHEMBL1075494
DR   Cosmic; 949094
DR   Cosmic; 1746953
DR   Cosmic; 2367537
DR   Cosmic-CLP; 949094
DR   DepMap; ACH-001118
DR   ENCODE; ENCBS062ILC
DR   ENCODE; ENCBS235AAA
DR   ENCODE; ENCBS304XWS
DR   ENCODE; ENCBS370AFW
DR   GDSC; 949094
DR   GEO; GSM326251
DR   GEO; GSM1374640
DR   GEO; GSM1670070
DR   IARC_TP53; 13244
DR   LINCS_LDP; LCL-1356
DR   PharmacoDB; M059J_877_2019
DR   Wikidata; Q54903415
RX   PubMed=7494872;
RX   PubMed=8316628;
RX   PubMed=10629611;
RX   PubMed=11023613;
RX   PubMed=11418067;
RX   PubMed=12105990;
RX   PubMed=18757420;
RX   PubMed=20164919;
RX   PubMed=25485619;
RX   PubMed=27397505;
RX   PubMed=30894373;
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/M059J_Stam_protocol.pdf
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Characteristics: Radiosensitive (PubMed=7494872).
CC   Karyotypic information: Has a near pentaploid phenotype.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Heterozygous for PRKDC p.Thr1351Profs*8 (c.4051delA) (PubMed=11418067; CCLE).
CC   Sequence variation: Homozygous for PTEN p.Pro204fs*17 (c.610delC) (ATCC; CCLE; Cosmic-CLP).
CC   Sequence variation: Homozygous for TP53 p.Glu286lys (c.856G>A) (PubMed=11023613; CCLE; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.01%; Native American=0%; East Asian, North=2.75%; East Asian, South=0%; South Asian=0%; European, North=67.68%; European, South=28.55% (PubMed=30894373).
CC   Caution: Was incorrectly stated to have deleterious mutations in ATM in PubMed=12105990.
ST   Source(s): ATCC; Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X,Y (ATCC; Cosmic-CLP)
ST   Amelogenin: X (PubMed=25877200)
ST   CSF1PO: 10,12 (ATCC; Cosmic-CLP)
ST   CSF1PO: 10 (PubMed=25877200)
ST   D13S317: 14
ST   D16S539: 10,12
ST   D18S51: 15,19
ST   D21S11: 30,31.2
ST   D3S1358: 14
ST   D5S818: 11,12 (ATCC; Cosmic-CLP)
ST   D5S818: 12 (PubMed=25877200)
ST   D7S820: 10,12 (ATCC; Cosmic-CLP)
ST   D7S820: 10 (PubMed=25877200)
ST   D8S1179: 15
ST   FGA: 20
ST   Penta D: 12,13
ST   Penta E: 7
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_0401 ! M059K
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 29
//
RX   PubMed=7494872; DOI=10.2307/3578948;
RA   Allalunis-Turner M.J., Zia P.K.Y., Barron G.M., Mirzayans R.,
RA   Day R.S. III;
RT   "Radiation-induced DNA damage and repair in cells of a radiosensitive
RT   human malignant glioma cell line.";
RL   Radiat. Res. 144:288-293(1995).
//
RX   PubMed=8316628; DOI=10.2307/3578196;
RA   Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D.,
RA   Mirzayans R.;
RT   "Isolation of two cell lines from a human malignant glioma specimen
RT   differing in sensitivity to radiation and chemotherapeutic drugs.";
RL   Radiat. Res. 134:349-354(1993).
//
RX   PubMed=10629611; DOI=10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2;
RA   Hoppe B.S., Jensen R.B., Kirchgessner C.U.;
RT   "Complementation of the radiosensitive M059J cell line.";
RL   Radiat. Res. 153:125-130(2000).
//
RX   PubMed=11023613; DOI=10.1667/0033-7587(2000)154[0473:HTFTMG]2.0.CO;2;
RA   Anderson C.W., Allalunis-Turner M.J.;
RT   "Human TP53 from the malignant glioma-derived cell lines M059J and
RT   M059K has a cancer-associated mutation in exon 8.";
RL   Radiat. Res. 154:473-476(2000).
//
RX   PubMed=11418067; DOI=10.1667/0033-7587(2001)156[0002:FMIPTG]2.0.CO;2;
RA   Anderson C.W., Dunn J.J., Freimuth P.I., Galloway A.M.,
RA   Allalunis-Turner M.J.;
RT   "Frameshift mutation in PRKDC, the gene for DNA-PKcs, in the DNA
RT   repair-defective, human, glioma-derived cell line M059J.";
RL   Radiat. Res. 156:2-9(2001).
//
RX   PubMed=12105990; DOI=10.1667/0033-7587(2002)158[0195:DOAGMI]2.0.CO;2;
RA   Tsuchida R., Yamada T., Takagi M., Shimada A., Ishioka C., Katsuki Y.,
RA   Igarashi T., Chessa L., Delia D., Teraoka H., Mizutani S.;
RT   "Detection of ATM gene mutation in human glioma cell line M059J by a
RT   rapid frameshift/stop codon assay in yeast.";
RL   Radiat. Res. 158:195-201(2002).
//
RX   PubMed=18757420; DOI=10.1158/0008-5472.CAN-08-0545;
RA   Burdak-Rothkamm S., Rothkamm K., Prise K.M.;
RT   "ATM acts downstream of ATR in the DNA damage response signaling of
RT   bystander cells.";
RL   Cancer Res. 68:7059-7065(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//